Abstract
Background/objective: Pharmacotherapy for heart failure is complex and, due to polypharmacy, is associated with a large risk of potential drug-drug interactions (DDIs). The objective of the present study was to assess the prevalence of potential DDIs in the medication of hospitalised heart failure patients and to evaluate their clinical relevance.
Study design/methods: The medication of 400 patients was retrospectively analysed for potential DDIs at hospital admission and discharge using a computerised drug interaction program. Main inclusion criteria were the diagnosis of heart failure and a minimum of two drug prescriptions at discharge.
Results: In the study population of 400 heart failure patients (median age 79 years, 55.5% men), the median number of drugs per patient was lower at admission than at discharge (6 [interquartile range {IQR} 4–9] vs 8 [IQR 6–10]; p < 0.001). At hospital admission, a total of 863 potential DDIs were detected in 272 patients (68.0%; 95% CI 63.4, 72.6). At discharge, 1171 potential DDIs were detected in 355 patients (88.8%; 95% CI 85.7, 91.8). This corresponds with a significant increase in the median number of potential DDIs per patient from admission to discharge (1.5 [IQR 0–3] vs 3 [IQR 1–4]; p < 0.001). Of the 1171 potential DDIs at discharge, 432 (36.9%) were prevalent at admission and 739 (63.1%) resulted from a medication change during the hospital stay. Of these 739 new potential DDIs, the severity of the potential adverse effect was rated as ‘major’ in 190 (25.7%) patients, ‘moderate’ in 482 (65.2%) and ‘minor’ in 67 (9.1%). The 190 potential DDIs with major severity were recorded in a total of 145 patients (36.3%; 95% CI 31.5, 41.0%). Hyperkalaemia was the most prevalent potential adverse effect of major severity (n = 93) and the combination of an ACE inhibitor with a potassium-sparing diuretic was recorded in 64 (16.0%) patients.
Conclusions: The study shows that hospitalisation of patients with heart failure results in an increase in the number of drugs prescribed per patient and, thereby, also in the number of potentially interacting drug combinations per patient. Although electronic drug interaction programs are a valuable tool to check for potential DDIs, the clinical relevance of most potential DDIs can only be judged by assessment of the individual patient.
Similar content being viewed by others
References
Masoudi FA, Krumholz HM. Polypharmacy and comorbidity in heart failure. BMJ 2003; 327(7414): 513–4
Ledwidge M, Travers B, Ryder M, et al. Specialist care of heart failure improves appropriate pharmacotherapy at the expense of greater polypharmacy and drug-interactions. Eur J Heart Fail 2004; 6(2): 235–43
Martinez-Selles M, Garcia Robles JA, Munoz R, et al. Pharmacological treatment in patients with heart failure: patients knowledge and occurrence of polypharmacy, alternative medicine and immunizations. Eur J Heart Fail 2004; 6(2): 219–26
Seymour RM, Routledge PA. Important drug-drug interactions in the elderly. Drugs Aging 1998; 12(6): 485–94
Köhler GI, Bode-Boger SM, Busse R, et al. Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther 2000; 38(11): 504–13
Ratz Bravo A, Tchambaz L, Krahenbuhl-Melcher A, et al. The prevalence of potentially critical drug-drug interactions in ambulatory dyslipidemic patients treated with statins. Drug Saf 2005; 28(3): 263–75
Bjerrum L, Andersen M, Petersen G, et al. Exposure to potential drug interactions in primary health care. Scand J Prim Health Care 2003; 21(3): 153–8
Egger SS, Drewe J, Schlienger RG. Potential drug-drug interactions in the medication of medical patients at hospital discharge. Eur J Clin Pharmacol 2003; 58(11): 773–8
Krum H, Gilbert RE. Demographics and concomitant disorders in heart failure. Lancet 2003; 362(9378): 147–58
Rosholm JU, Bjerrum L, Hallas J, et al. Polypharmacy and the risk of drug-drug interactions among Danish elderly: a prescription database study. Dan Med Bull 1998; 45(2): 210–3
Bergk V, Gasse C, Rothenbacher D, et al. Drug interactions in primary care: impact of a new algorithm on risk determination. Clin Pharmacol Ther 2004; 76(1): 85–96
Bergendal L, Friberg A, Schaffrath A. Potential drug-drug interactions in 5,125 mostly elderly out-patients in Gothenburg, Sweden. Pharm World Sci 1995; 17(5): 152–7
Björkman IK, Fastbom J, Schmidt IK, et al. Drug-drug interactions in the elderly. Ann Pharmacother 2002; 36(11): 1675–81
Jankel CA, Fitterman LK. Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Saf 1993; 9(1): 51–9
Di Castri A, Jacquot JM, Hemmi P, et al. Intéractions médicamenteuses: etudes de 409 ordonnances établies à l’issue d’une hospitalisation gériatrique. Therapie 1995; 50(3): 259–64
Dettli L. Drug dosage in patients with renal disease. Clin Pharmacol Ther 1974; 16(1): 274–80
Klasco RK, Moore LE. Drug-Reax® System. Greenwood Village (CO): MICROMEDEX, 2004
Gaddis GM, Holt TR, Woods M. Drug interactions in at-risk emergency department patients. Acad Emerg Med 2002; 9(11): 1162–7
Langdorf MI, Fox JC, Marwah RS, et al. Physician versus computer knowledge of potential drug interactions in the emergency department. Acad Emerg Med 2000; 7(11): 1321–9
Meredith PA. Is postural hypotension a real problem with antihypertensive medication? Cardiology 2001; 96Suppl. 1: 19–24
Mignat C, Unger T. ACE inhibitors: drug interactions of clinical significance. Drug Saf 1995; 12(5): 334–47
Tan LB, Williams SG, Goldspink DF. From CONSENSUS to CHARM: how do ACEI and ARB produce clinical benefits in CHF? Int J Cardiol 2004; 94(2-3): 137–41
Klein L, O’Connor CM, Gattis WA, et al. Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations. Am J Cardiol 2003; 91(9A): 18F–40F
Bouvy ML, Heerdink ER, Leufkens HG, et al. Patterns of pharmacotherapy in patients hospitalised for congestive heart failure. Eur J Heart Fail 2003; 5(2): 195–200
Ageno W, Turpie AG. Low molecular weight heparins in the treatment of unstable angina. Minerva Cardioangiol 2002; 50(6): 643–51
Shullo MA, Rose ML, Vivas C, et al. Hemorrhagic complications of enoxaparin and aspirin in patients with kidney transplants. Pharmacotherapy 2002; 22(2): 184–7
Farooq V, Hegarty J, Chandrasekar T, et al. Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease. Am J Kidney Dis 2004; 43(3): 531–7
Haustein KO. Pharmacokinetic and pharmacodynamic properties of oral anticoagulants, especially phenprocoumon. Semin Thromb Hemost 1999; 25(1): 5–11
Perazella MA. Drug-induced hyperkalemia: old culprits and new offenders. Am J Med 2000; 109(4): 307–14
McAlister FA, Ezekowitz J, Tonelli M, et al. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 2004; 109(8): 1004–9
Schepkens H, Vanholder R, Billiouw JM, et al. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 2001; 110(6): 438–41
Svensson M, Gustafsson F, Galatius S, et al. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail 2004; 10(4): 297–303
Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors: how much should we worry? Arch Intern Med 1998; 158(1): 26–32
Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341(10): 709–17
Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351(6): 543–51
Morimoto T, Gandhi TK, Fiskio JM, et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract 2004; 10(4): 499–509
Leor J, Levartowsky D, Sharon C, et al. Amiodarone and betaadrenergic blockers: an interaction with metoprolol but not with atenolol. Am Heart J 1988; 116(1 Pt 1): 206–7
Yamreudeewong W, DeBisschop M, Martin L, et al. Potentially significant drug interactions of class III antiarrhythmic drugs. Drug Saf 2003; 26(6): 421–38
Boutitie F, Boissel JP, Connolly SJ, et al. Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators. Circulation 1999; 99(17): 2268–75
Krum H, Shusterman N, MacMahon S, et al. Efficacy and safety of carvedilol in patients with chronic heart failure receiving concomitant amiodarone therapy. Australia/New Zealand Heart Failure Research Collaborative Group. J Card Fail 1998; 4(4): 281–8
Herrlinger C, Klotz U. Drug metabolism and drug interactions in the elderly. Best Pract Res Clin Gastroenterol 2001; 15(6): 897–918
Juurlink DN, Mamdani MM, Kopp A, et al. A population-based assessment of the potential interaction between serotonin-specific reuptake inhibitors and digoxin. Br J Clin Pharmacol 2005; 59(1): 102–7
Chen YF, Avery AJ, Neil KE, et al. Incidence and possible causes of prescribing potentially hazardous/contraindicated drug combinations in general practice. Drug Saf 2005; 28(1): 67–80
Egger T, Dormann H, Ahne G, et al. Identification of adverse drug reactions in geriatric inpatients using a computerised drug database. Drugs Aging 2003; 20(10): 769–76
Acknowledgements
The present study was not funded. None of the authors have any conflicts of interest directly relevant to the content of this study.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Straubhaar, B., Krähenbühl, S. & Schlienger, R.G. The Prevalence of Potential Drug-Drug Interactions in Patients with Heart Failure at Hospital Discharge. Drug-Safety 29, 79–90 (2006). https://doi.org/10.2165/00002018-200629010-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-200629010-00006